Emergent BioSolutions Inc. EBS
NYSE
| 09/30/2026 | 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -52.40% | 66.29% | -29.75% | -23.63% | -21.34% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -52.40% | 66.29% | -29.75% | -23.63% | -21.34% |
| Cost of Revenue | -14.55% | 32.96% | -19.69% | -23.58% | -23.61% |
| Gross Profit | -80.77% | 109.82% | -38.38% | -23.71% | -19.55% |
| SG&A Expenses | 3.86% | 2.06% | -11.07% | -12.87% | -40.97% |
| Depreciation & Amortization | -34.97% | 6.17% | 1.23% | 0.00% | 0.00% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -11.98% | 20.19% | -15.06% | -18.04% | -27.10% |
| Operating Income | -133.77% | 5,433.33% | -79.17% | -58.04% | -6.46% |
| Income Before Tax | -163.19% | -889.88% | -85.54% | -83.70% | -59.55% |
| Income Tax Expenses | -157.81% | 389.58% | -73.28% | 5.41% | -76.81% |
| Earnings from Continuing Operations | -163.87% | -1,401.67% | -90.00% | -74.44% | -55.40% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -163.87% | -1,401.67% | -90.00% | -74.44% | -55.40% |
| EBIT | -133.77% | 5,433.33% | -79.17% | -58.04% | -6.46% |
| EBITDA | -109.33% | 271.49% | -55.75% | -83.10% | -7.43% |
| EPS Basic | -166.23% | -1,477.33% | -89.52% | -80.43% | -55.49% |
| Normalized Basic EPS | -137.13% | 444.48% | -71.24% | 139.19% | -40.80% |
| EPS Diluted | -170.33% | -1,477.33% | -93.76% | -79.75% | -55.83% |
| Normalized Diluted EPS | -139.43% | 444.48% | -72.18% | 139.19% | -41.63% |
| Average Basic Shares Outstanding | -3.57% | -4.80% | -4.60% | -3.32% | 0.19% |
| Average Diluted Shares Outstanding | -9.20% | -4.80% | -1.40% | -3.32% | 1.62% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |